Introduction
============

Cervical cancer is the second most common type of cancer among women globally, particularly in developing countries ([@b1-ol-0-0-3998],[@b2-ol-0-0-3998]). Radical hysterectomy is the primary treatment for early-stage cervical cancer, and has demonstrated a 5-year overall survival rate of 80--90% ([@b2-ol-0-0-3998],[@b3-ol-0-0-3998]). For patients exhibiting high-risk factors or locally advanced disease, postoperative adjuvant concurrent radiochemotherapy is typically recommended, which has been confirmed to reduce locoregional recurrence ([@b4-ol-0-0-3998]--[@b7-ol-0-0-3998]). However, there is a high incidence of radiation-induced toxicities of pelvic normal tissue, leading to a severely negative influence on patient quality of life ([@b8-ol-0-0-3998]). Furthermore, \~30% of cervical cancer patients exhibiting stages IB2 to IV (International Federation of Gynecology and Obstetrics, FIGO) typically relapse following treatment ([@b8-ol-0-0-3998],[@b9-ol-0-0-3998]). In theory, a higher radiation dose directed at the target will reduce the likelihood of disease relapse, while potentially increasing the exposure of organs at risk (OARs), which in turn will limit the delivery of higher doses to the target. Therefore, it is important to utilize a treatment technique that is able to deliver an adequate dose to the tumor volume, while minimizing exposure of the OARs.

Intensity-modulated radiation therapy (IMRT) techniques have been widely utilized in a number of countries, and have produced improved dose distribution and OAR sparing compared with conventional radiotherapy, decreasing radiation-induced toxicity ([@b10-ol-0-0-3998]--[@b12-ol-0-0-3998]). Positive dose distribution and patient outcomes achieved by IMRT have been observed in several clinical studies ([@b13-ol-0-0-3998]--[@b16-ol-0-0-3998]). However, IMRT has additionally presented certain disadvantages, one of which is that the treatment delivery time is prolonged ([@b17-ol-0-0-3998]). Volumetric-modulated arc therapy (VMAT), a complex form of IMRT, has received considerable attention in the radiation oncology field, and has been investigated in a variety of malignant tumors, including esophageal, prostate and small brain tumors ([@b17-ol-0-0-3998]--[@b19-ol-0-0-3998]). Cozzi *et al* ([@b20-ol-0-0-3998]) reported that a RapidArc (RA) treatment plan for the treatment of cervical uterine cancer demonstrated improved sparing of OARs and healthy tissue, with uncompromising target coverage compared with fixed field (f)-IMRT. However, Zhai *et al* ([@b21-ol-0-0-3998]) concluded alternative results, demonstrating that f-IMRT possessed improved conformal planning target volume (PTV) coverage and OAR sparing, compared with VMAT, for the treatment of cervical cancer. Therefore, in the present study, a dosimetric comparison of VMAT and f-IMRT techniques was conducted in order to clarify whether VMAT possessed a dosimetric advantage in dose distribution of PTV and sparing of OARs compared with f-IMRT, thus achieving an optimization for the treatment planning for cervical cancer patients exhibiting stage IB-IIA high-risk cervical cancer following hysterectomy.

Materials and methods
=====================

### Patients

A total of 15 patients (Karnofsky Performance Status; KPS\>70) exhibiting stage IB-IIA cervical cancer with high-risk factors, who had received postoperative adjuvant concurrent radiochemotherapy (cisplatin-based chemotherapy and external beam radiotherapy for 45--50 Gy) between March and November 2012 at the Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University (Jinan, China), were selected for the present study. According to FIGO, the clinical stages of all patients were as follows: 9 patients were stage IB and 6 were stage IIA. All patients underwent radical hysterectomy and pelvic lymph node dissection. The high-risk factors included pelvic lymph node metastases, parametrial invasion and positive surgical margins. Patient ages ranged from 34--59 years, with a median age of 43 years. Detailed patient information is listed in [Table I](#tI-ol-0-0-3998){ref-type="table"}.

The present study was approved by the Qianfoshan Hospital Ethics Committee, and informed consent was obtained from all patients.

### Target volume and organs at risk delineation

All patients were immobilized in a supine position with bladder filling, and stimulated utilizing a computed tomography (CT) scanner with a 3 mm slice thickness from the superior margin of the L4 to the ischial tuberosities. According to the consensus guidelines of Taylor *et al* ([@b22-ol-0-0-3998]), the target volumes were delineated by an experienced radiation oncologist and radiologist. The clinical target volume (CTV) included the upper 3.0 cm of the vagina, paravaginal soft tissue lateral to the vagina and pelvic lymph node regions (the common iliac, external and internal iliac, and presacral lymph nodes). The PTV was generated by using 1 cm uniform expansion of the CTV in all directions, based on the guidelines set out by Small *et al* ([@b23-ol-0-0-3998]). The OARs that were contoured comprised the bladder, rectum, small bowel and femoral heads. The rectum was defined from the level of the rectosigmoid junction to the anus. The bladder was contoured entirely. The small bowel was contoured from the interspace of L4--5 to its lowest extent in the pelvis. The femoral heads were delineated from the cranial end point to the lower margin of the ischial tuberosities.

### Dose prescription and constraints

VMAT and f-IMRT treatment plans were designed for a treatment in 25 fractions, with the aim of delivering a total dose of 50 Gy to the PTV, using the Eclipse™ Treatment Planning System (Version 10.0; Varian Medical Systems, Inc., Palo Alto, CA, USA), with a 6 MV beam modulator linear accelerator (TrueBeam; Varian Medical Systems, Inc.). The treatment plans aimed to cover ≥95% of the volume of PTV with the prescribed dose, and to restrict a mean dose of \<105% and a maximum dose of \<110% of the prescribed dose. The dose delivered to 50% of the tumor volume was \<45 Gy for the bladder, and 50 Gy for the rectum and the small bowel. For the femoral heads, the dose delivered to 5% of the tumor volume was \<45 Gy.

### IMRT and VMAT treatment plans

f-IMRT treatment plans were optimized with a Dose Volume Optimizer engine (version 10.0.28; Varian Medical Systems, Palo Alto, CA, USA), and dose calculation was performed by anisotropic analytical algorithm. The f-IMRT treatment plans were performed using five coplanar fields (5F) with the dynamic sliding window technique, as 5F-IMRT is widely used as a treatment choice for eligible patients at Qianfoshan Hospital. Each treatment field constituted beam geometry, with the following gantry angles: 0°/72°/144°/216°/288°.

The VMAT treatment plans were optimized with the Progressive Resolution Optimizer (PRO; version 10.0.28; Varian Medical Systems, Palo Alto, CA, USA). Two full arcs were used in the VMAT treatment plans, which consisted of two coplanar arcs of 360° with opposite rotation. The first arc rotated clockwise for 358° and started with a gantry angle of 181° to stop at 179°, while the second arc rotated anticlockwise from the gantry angle of 179° to 181°. The couch was set to 0°, and the collimator angle was set to 30° (or 330°) to avoid tongue-and-groove effects. Each arc was limited to a sequence of 178 control points. Two coplanar arcs allowed superior modulation factors during optimization, which contributed to acquiring higher target homogeneity and improved OAR sparing.

VMAT and f-IMRT plans were exported by Digital Imaging and Communication in Medicine (DICOM; Varian Medical Systems, Palo Alto, CA, USA) radiotherapy export.

### Evaluation parameters

Data from the dose volume histograms acquired for each patient were analyzed. For the target-dose coverage, a set of dosimetric parameters was analyzed, including the mean dose (Dmean), maximum dose, V95% (i.e. the percent of the tumor volume that received x% of the prescribed dose), V105%, conformity index (CI) and homogeneity index (HI).

CI, as a means to assess the conformity of dose distribution, was calculated as follows:
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In which, PTV100 was the target volume covered by the prescribed dose, PTV was the target volume and V100 was the volume of the prescribed dose. Higher values (close to 1) of CI represented an improved PTV conformity. HI was defined as follows:

H

I

=

D

5

\%

D

95

\%

![](ol-11-02-0959-g01.jpg)

In which, Dx% represented the dose delivered to x% of the PTV. Lower values (close to 1) of HI indicated a more homogenous PTV dose distribution.

To investigate the evaluation parameters of OARs, for bladder, rectum and small bowel, a series of Vx values were analyzed respectively, and for femoral heads, the D5 from the two treatment plans were compared.

For each patient, treatment time and the number of MUs were evaluated. Patient positioning, gantry and collimator rotation times were excluded when treatment time was recorded.

### Statistical analysis

All statistical analyses of VMAT and f-IMRT treatment plans were performed using SPSS (Version 13.0; SPSS, Inc., Chicago, IL, USA). Paired sample t-test was utilized for the calculation of statistical difference. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Target-dose coverage is slightly reduced in VMAT compared with f-IMRT

VMAT and f-IMRT treatment plans of all 15 patients were completed according to the aforementioned design. The dosimetric parameters associated with the target of the two treatment plans are presented in [Table II](#tII-ol-0-0-3998){ref-type="table"}. The dose distribution of VMAT and f-IMRT treatment plans in a single representative patient is revealed in [Fig. 1](#f1-ol-0-0-3998){ref-type="fig"}. The results of the present study indicated that VMAT demonstrated an equivalent dose coverage to the target compared with f-IMRT.

The maximum dose to the PTV was slightly increased for f-IMRT compared with VMAT, but no significant difference was observed between the two treatment plans (P\>0.05). Regarding the comparison of Dmean, a similar trend was identified (51.06±0.14 Gy for f-IMRT vs. 50.93±0.24 Gy for VMAT; P=0.295). There was no significant difference between the two plans in the comparison of V95% and V105% (P\>0.05).

Conformity was improved in VMAT compared with f-IMRT, and a statistically significant difference was identified (0.82±0.01 vs. 0.78±0.04, respectively; P\<0.05). However, there was no significant difference between VMAT and f-IMRT in terms of HI (1.03±0.08 vs. 1.04±0.01; P\>0.05).

### OAR sparing is largely superior in VMAT

Parameters associated with the dose delivered to OARs for VMAT and f-IMRT are revealed in [Table III](#tIII-ol-0-0-3998){ref-type="table"}. [Fig. 2](#f2-ol-0-0-3998){ref-type="fig"} illustrates the differences between the VMAT and f-IMRT treatment plans in a single representative patient.

For the bladder, f-IMRT was superior to VMAT for OAR sparing at V20 and V30, and this difference was statistically significant (P\<0.05). However, the advantage for f-IMRT was not observed with regard to V40 (55.30±9.38% for f-IMRT vs. 51.40±8.90% for VMAT; P\>0.05). V50 for f-IMRT was, on average, higher than VMAT, with a statistically significant difference (21.79±5.71% for f-IMRT vs. 17.82±7.15% for VMAT; P\<0.05). For the rectum, a similar trend of dose distribution (V10, V20 and V30) was observed between the two techniques (V10, P=0.012; V20, P=0.063; V30, P\<0.0001). Compared with f-IMRT, V40 was slightly lower in VMAT (65.34±13.30 vs. 66.65±13.41%; P\<0.05). A statistically significant difference was observed for V50 between the VMAT and f-IMRT treatment plans (22.37±8.30 vs. 22.08±7.58%; P\<0.05). For the small bowel, V10 in f-IMRT was slightly lower compared with that observed in VMAT (78.53±14.30 vs. 80.27±23.14%; P\<0.05). However, an adverse trend was observed in terms of V20, V30, V40 and V50, and VMAT was slightly improved compared with f-IMRT for these parameters (P\<0.05). For ambilateral femoral heads, VMAT demonstrated a slight advantage compared with f-IMRT (P\<0.05).

### Treatment time and monitor units are reduced in VMAT

The treatment time by VMAT was 1.06 min, which was \~2.7 times shorter compared with f-IMRT (1.06±0.14 vs. 2.87±0.27 min). For MU, a significant reduction was observed for VMAT compared with f-IMRT (377.75±45.83 vs. 1,147.38±107.34). Details are presented in [Table II](#tII-ol-0-0-3998){ref-type="table"}.

Discussion
==========

In the present study, a series of dosimetric parameters indicated that VMAT and f-IMRT treatment plans were able to meet the requirements for target coverage and OAR sparing. Furthermore, VMAT exhibited a similar or improved dose distribution to the target and sparing of OARs compared with f-IMRT, and significantly reduced the treatment time and MU number. Similar results were observed by Cozzi *et al* ([@b20-ol-0-0-3998]) and Palma *et al* ([@b24-ol-0-0-3998]). However, the results of the present study were not consistent with those of Zhai *et al* ([@b21-ol-0-0-3998]) and Yoo *et al* ([@b25-ol-0-0-3998]), in which f-IMRT demonstrated improved conformal PTV coverage and OAR sparing compared with RA. This difference may be due to the discrepancy between target volume delineation and treatment plan formulations.

VMAT, as a rotational form of IMRT, enables dose delivery primarily in single or double arcs ([@b20-ol-0-0-3998]). In the present study, dual arcs were utilized, which have resulted in superior modulation factor during optimization and highly conformal dose by varying the speed of gantry rotation, the multileaf collimator shape and the dose rate. Verbakel *et al* ([@b26-ol-0-0-3998]) demonstrated that dual-arc VMAT treatment plans produced similar or improved OAR sparing, and superior target dose homogeneity, compared with single-arc VMAT in head and neck cancer. In addition, a study performed by Guckenberger *et al* ([@b27-ol-0-0-3998]) indicated that dual-arc VMAT may improve target coverage and dose homogeneity compared with single-arc VMAT. Furthermore, considering the complexity of the target volume and importance of critical organ sparing, the present study selected dual-arc VMAT techniques that yielded a promising and clinically acceptable outcome for the current experiments.

Comparing VMAT with f-IMRT, the present study identified that the two techniques met the requirements of clinical treatment for PTV coverage. VMAT proved to be superior to f-IMRT in terms of CI, however, for HI this advantage was not observed. For the bladder, rectum and small bowel, f-IMRT was similar or slightly improved compared with VMAT at low dose levels of V10, V20 and V30. However, VMAT proved to be superior to f-IMRT at high dose levels of V40 or V50, particularly for the bladder. Therefore, VMAT may be preferentially used for the treatment of patients exhibiting cervical cancer with accompanying bladder disease, to improve bladder sparing. However, whether VMAT is able to reduce radiation-induced bladder injury or bring long-term clinical benefit remains to be elucidated, and requires further investigation by means of clinical studies. With regard to femoral heads, VMAT provided improved sparing by reducing the delivery dose compared with f-IMRT.

f-IMRT demonstrated an additional number of MUs compared with VMAT. The treatment time for f-IMRT was \~2.7 times longer than that for VMAT. The results of the present study suggested that VMAT may significantly reduce treatment time and MU number compared with f-IMRT, which may decrease the effects of intrafractional motion due to patient movement occurring during treatment delivery ([@b28-ol-0-0-3998]). Furthermore, the reduction in treatment time was capable of lessening the radiation effects to critical structures, which were adjacent to the target tumor volume ([@b29-ol-0-0-3998]), and the reduction of MU may decrease the number of radiation-induced secondary cancers by reducing leakage radiation ([@b30-ol-0-0-3998]). In addition, Wang *et al* ([@b31-ol-0-0-3998]) demonstrated that prolonged delivery time of \>10--15 min may reduce tumor cell killing, due to increased sublethal damage repair. Moiseenko *et al* ([@b32-ol-0-0-3998]) investigated cell survival for three cervical carcinoma cell lines, which were irradiated for 75 s, 5 min and 10 min respectively, and identified that the survival rates of the three cell lines were 39, 53 and 59%, respectively. The above-mentioned studies indicate that short treatment time and reduced MU numbers contribute to the acquisition of a superior clinical outcome for local tumor control. Consequently, in the present study improved tumor control was observed following treatment with VMAT. However, the planning time used for VMAT was markedly increased compared with f-IMRT, as the computational speed of the optimization process was slower in VMAT than in f-IMRT for the planning systems utilized in the present study. However, when utilizing certain automatic scripts set up in advance, each plan may be completed in a short time.

The results of the present study may be influenced by the following limitations. Intrafractional organ motion may not have been detected due to an absence of a cone beam CT facility in the department, which may have influenced the results of dose delivery to the target and OARs. In addition, patient positioning and bladder filling status were not monitored due to a lack of image guidance. Furthermore, the present study was limited by a small sample size, which negated the precise evaluation of the dosimetric parameters between the two treatment plans.

Based on the results of the present study, it was concluded that in stage IB-IIA high-risk cervical cancer irradiation, the VMAT technique demonstrated certain advantages, not in superior dose distribution or OAR sparing, but in short treatment delivery time and low MU number. With additional performance of clinical studies, the advantages of VMAT techniques may be confirmed.

In the present study, VMAT and f-IMRT techniques met the clinical requirements for dose distribution and OAR sparing. VMAT techniques proved to generate similar PTV coverage compared with f-IMRT. However, VMAT led to a reduction of OAR volumes irradiated at high dose levels in comparison with f-IMRT, particularly for the bladder, significantly reducing the treatment time and MU number.

The present study was supported by the Natural Science Foundation of Shandong Province (grant no. ZR2012HM095).

![Dose distributions of the VMAT and IMRT plans in a single representative patient by horizontal view (A and D), coronal view (B and E) and sagittal view (C and F). (A-C) VMAT dose distribution. (D-F) IMRT dose distribution. Red line, planning target volume; Orange line, clinical target volume. VMAT, volumetric-modulated arc therapy; IMRT, intensity-modulated radiotherapy.](ol-11-02-0959-g02){#f1-ol-0-0-3998}

![Dose-volume histogram of a representative patient for VMAT and IMRT. (A) VMAT, (B) IMRT. Red line (−), planning target volume; Orange line (−), clinical target volume; Dark blue line (−), bladder; Magenta line (−), rectum; Yellow line (−), small bowel; Cyan line (−), left femur; Brown line (−), right femur. VMAT, volumetric-modulated arc therapy; IMRT, intensity-modulated radiotherapy.](ol-11-02-0959-g03){#f2-ol-0-0-3998}

###### 

Patient characteristics.

  Variable                                                                 Value
  ------------------------------------------------------------------------ --------
  Age, years                                                               
    Mean                                                                   43
    Range                                                                  34--59
  Stage^[a](#tfn1-ol-0-0-3998){ref-type="table-fn"}^, number of patients   
    IB                                                                     9
    IIA                                                                    6
  Histology, number of patients                                            
    Squamous carcinoma                                                     10
    Adenocarcinoma                                                         5

According to the International Federation of Gynecology and Obstetrics.

###### 

Comparison of the dosimetric parameters of the planning target volume, MU and treatment time.

  Variable   IMRT             VMAT           P-value
  ---------- ---------------- -------------- ---------
  Dmax       52.97±0.26       52.62±0.32     0.219
  Dmean      51.06±0.14       50.93±0.24     0.295
  V95%       99.86±0.06       99.96±0.03     0.739
  V105%        0.33±0.47        0.24±0.42    0.342
  CI           0.78±0.04        0.82±0.01    0.010
  HI           1.04±0.01        1.03±0.08    0.718
  MU         1147.38±107.34   377.75±45.83   0.946
  Time         2.87±0.27        1.06±0.14    0.552

IMRT, intensity-modulated radiotherapy; VMAT, volumetric-modulated arc therapy; Dmax, maximal dose; Dmean, mean dose; Vx%, target tumor volume covered by X% of the prescribed dose; CI, conformity index; HI, homogeneity index; MU, monitor unit.

###### 

Comparison of the dosimetric parameters of the organs at risk.

  Variable                 IMRT          VMAT          P-value
  ------------------------ ------------- ------------- ---------
  Bladder, %                                           
    V10                    99.96±0.11    100.00±0.00   0.344
    V20                    97.62±5.09    99.79±0.49    0.000
    V30                    84.32±8.64    84.42±14.89   0.003
    V40                    55.30±9.38    51.40±8.90    0.199
    V50                    21.79±5.71    17.82±7.15    0.012
  Rectum, %                                            
    V10                    97.92±3.38    98.34±2.78    0.012
    V20                    96.65±3.90    97.52±2.57    0.063
    V30                    88.45±9.82    91.87±7.99    0.000
    V40                    66.65±13.41   65.34±13.30   0.000
    V50                    22.08±7.58    22.37±8.30    0.000
  Small bowel, %                                       
    V10                    78.53±14.30   80.27±23.14   0.003
    V20                    57.78±16.77   56.59±18.69   0.001
    V30                    38.22±11.89   34.64±12.54   0.000
    V40                    20.65±8.79    19.42±11.87   0.000
    V50                    7.81±5.25     7.40±5.40     0.000
  Left femoral head, Gy                                
    D5                     38.26±4.35    37.80±4.36    0.000
  Right femoral head, Gy                               
    D5                     37.27±4.49    36.13±4.35    0.005

IMRT, intensity-modulated radiotherapy; VMAT, volumetric-modulated arc therapy; Vx, target tumor volume covered by X Gy; D5, dose delivered to 5% of the femoral head.
